Key information

Title
Combination of oils
Application number
20171033
Case type
National
Status
12.08.2019 Patent meddelt (B1)
Filed
23.06.2017
Effective date
23.06.2017
Publicly available
24.12.2018
Next annual fee due
30.06.2027
Applicant
OliVita AS (NO)
Owner
ARCTIC OMEGA 3 NORWAY AS (NO)
Inventor
Bjarne Østerud (NO)
Agent
ZACCO NORWAY AS (NO)
Granted
12.08.2019
Patent number
344004
Expiry date
23.06.2037

Abstract and drawing

Disclaimer: This text has been machine-scanned and may contain errors – please refer to "Publications" for legally binding content.
A combination of oils as a supplement to, or component of, a regular diet, wherein it comprises marine oil, preferably herring oil, and cold-pressed virgin olive oil.

Publications

Latest published versionB1A1

Documents

 Expand Download files (32)
Date
 Date Doc. No. Process Case number In/Out Journal description To/from
 01.11.2022 16-01 Saksbehandling 20171033(344004) UT PT Påminnelse om ikke betalt årsavgift (3329) (PT20171033)
07.10.2020 02-01 Overdragelse av søknad/rettighet 2020/12089 UT GH Forespørsel ZACCO NORWAY AS
 28.09.2020 01-02 Overdragelse av søknad/rettighet 2020/12089 INN Fullmakt ZACCO NORWAY AS
 28.09.2020 01-01 Overdragelse av søknad/rettighet 2020/12089 INN Generell henvendelse ZACCO NORWAY AS
 16.08.2019 15-01 Saksbehandling 20171033 UT PT Registreringsbrev Nasjonal Patent (15) (PT20171033)
05.06.2019 14-01 Saksbehandling 20171033 UT PT Meddelelse om patent ZACCO NORWAY AS
 28.05.2019 13-02 Saksbehandling 20171033 INN Krav ZACCO NORWAY AS
 28.05.2019 13-01 Saksbehandling 20171033 INN Korrespondanse (Hovedbrev inn) ZACCO NORWAY AS
 20.05.2019 12-04 Saksbehandling 20171033 INN Beskrivelse merket ZACCO NORWAY AS
 20.05.2019 12-03 Saksbehandling 20171033 INN Beskrivelse ren ZACCO NORWAY AS
 20.05.2019 12-02 Saksbehandling 20171033 INN Hovedbrev ZACCO NORWAY AS
 20.05.2019 12-01 Saksbehandling 20171033 INN Korrespondanse (Hovedbrev inn) ZACCO NORWAY AS
 07.05.2019 11-01 Saksbehandling 20171033 UT PT Varsel om betaling av første årsavgift (3317) (PT20171033)
02.05.2019 10-02 Saksbehandling 20171033 UT PT_report 12:15:01
02.05.2019 10-01 Saksbehandling 20171033 UT Realitet patent ZACCO NORWAY AS
 31.08.2018 09-02 Saksbehandling 20171033 INN Hovedbrev ZACCO NORWAY AS
 31.08.2018 09-01 Saksbehandling 20171033 INN Korrespondanse (Hovedbrev inn) ZACCO NORWAY AS
 14.06.2018 07-01 Saksbehandling 20171033 UT Bekreftelse på patentsøknad ZACCO NORWAY AS
 13.06.2018 08-01 Saksbehandling 20171033 INN Korrespondanse (Hovedbrev inn) ZACCO NORWAY AS
 13.06.2018 06-01 Saksbehandling 20171033 UT Realitet patent ZACCO NORWAY AS
 08.06.2018 05-03 Saksbehandling 20171033 INN Hovedbrev ZACCO NORWAY AS
 08.06.2018 05-02 Saksbehandling 20171033 INN Sammenlikningseksempel ZACCO NORWAY AS
 08.06.2018 05-01 Saksbehandling 20171033 INN Korrespondanse (Hovedbrev inn) ZACCO NORWAY AS
 26.04.2018 04-02 Saksbehandling 20171033 INN Hovedbrev ZACCO NORWAY AS
 26.04.2018 04-01 Saksbehandling 20171033 INN Korrespondanse (Hovedbrev inn) ZACCO NORWAY AS
 27.10.2017 03-02 Saksbehandling 20171033 UT PT report 01:15:14
27.10.2017 03-01 Saksbehandling 20171033 UT Realitet patent Zacco Norway AS
 28.06.2017 02-01 Saksbehandling 20171033 UT Infobrev til oppfinner Zacco Norway AS
 23.06.2017 01-04 Saksbehandling 20171033 INN Erklæring Søkers rett til oppfinnelse Zacco Norway AS
 23.06.2017 01-03 Saksbehandling 20171033 INN Beskrivelse Zacco Norway AS
 23.06.2017 01-02 Saksbehandling 20171033 INN Fullmakt Zacco Norway AS
 23.06.2017 01-01 Saksbehandling 20171033 INN Søknadsskjema Patent Zacco Norway AS

Description, claims and drawings

Disclaimer: This text has been machine-scanned and may contain errors – please refer to "Publications" for legally binding content. Description
FIELD OF INVENTIONThe present invention relates to a combination of oils as a supplement to, or component of, a regular diet to counteract the development of coronary heart disease (CHD), thrombosis and other inflammatory diseases such as psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia etc. in addition to preventnon-alcoholic fatty liver disease (NAFLD). The combination according to the invention comprises herring oil and cold-pressed (virgin) olive oil, optionally in mixtures with additive amounts of EPA, DHA and/or DPA.BACKGROUND OF THE INVENTIONAtherosclerotic lesions are formed when three cellular components of the circulation, monocytes, platelets and T-lymphocytes, react with LDL-cholesterol and two cell types in the artery wall, endothelial cells (EC) and the smooth muscle cells (SMC).The precursor of atherogenesis is the recruitment of monocytes and lymphocytes from the peripheral blood to the intima of the vessel wall, an event that appears to depend upon the local presence of large amounts of LDL. As LDL accumulates, bound lipid and protein are oxidized and glycosylated. Cells in the vessel wall seem to interpret this change as a danger signal and call for reinforcements from the body's defence system. These processes appear to promote an up-regulation of adhesion molecules on the endothelial cells, particularly vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1). Thus, monocyte and lymphocyte recruitment is initiated. This leads to increased transmigration of monocytes, up-regulated exposure of adhesion molecules on the endothelium, and the production and release of chemoattractants. These are essential events for the transfer of monocytes to the intima, and the concurrent differentiation of monocytes into macrophages. Available modified LDL is also a prerequisite for the further development of macrophages into foam cells (fatty macrophages), which is the main cause of the formation of fatty streaks under the endothelium of the vessel wall. Modified forms of LDL (oxidized, glycosylated etc.) are of particular interest since the modification of LDL is associated with inflammatory reactions triggered by processes that are initiated due to the adhesion and transmigration of monocytes and lymphocytes into the intima. As mentioned above, it is well known that monocytes play a central role in the early phase of atherogenesis. One of the first events in the atherosclerotic process is the mobilization of monocytes into the intima. Since the recruitment of monocytes and their penetration through the endothelium are associated with the secretion of activation products such as cytokines and growth factors, it may be assumed that the functional reactivity of the circulating monocytes is very important. It is suggested that chronic infectious diseases may affect the functional reactivity by activating the monocytes and making them more liable to produce and release harmful products such as cytokines and chemokines in response tostress.To date, little is known as to exactly how the functional properties of circulating monocytes relate to atherogenesis. However, it is well established that hyperactive monocytes play a crucial role in the pathophysiology of rheumatism, psoriasis and other inflammatory diseases. We also know that atherogenesis is apro-inflammatory disease. It may therefore be assumed that the pro-inflammatory function of circulating monocytes may be associated with increased risk of coronary heart disease (CHD), and that high cholesterol levels may augment production of pro-inflammatory products such as oxygen radicals, cytokines etc.For many years, the inventor has observed that the reactivity of monocytes, as monitored by the production of tissue factor (TF) and cytokines such as TNFa and IL-6 in lipopolysaccharide (LPS) stimulated blood, varies between individuals from low activity to very high activity (high responders). This property of monocytes seems to be hereditary (Østerud et al, "Blood Coagulation and Fibrinolysis" 2002; 13:399-405). The inventor has, inter alia, investigated in vitro howLPS-induced reactivity in monocytes in whole blood relates to the lipid profile in the serum of healthy individuals with a history of myocardial infarction (Ml) or cancer in their close family. Of a total of 54 individuals in the myocardial infarction (Ml) families, 20 had moderately high cholesterol (7.1 -10.2 mmol/1), whilst 34 had normal cholesterol. Of the individuals with normal cholesterol, 19 had hyperactive monocytes (high responders), whilst 15 had normally responding monocytes. LPS-induced TF, TNFa and IL-6 were on average 3-4 times higher in the group with normal cholesterol compared with the group with moderately high cholesterol. Thus, no positive correlation between hyperactive monocytes and cholesterol level was found. All 42 individuals in the families with a history of cancer had normal cholesterol, and LPS-induced thromboplastin (TF), TNFa and IL-6 were not significantly different from the values of the group with moderately high cholesterol among the myocardial infarction (Ml) families. This supports the conclusion that moderately high cholesterol is not associated with increased monocyte activation in whole blood, whilst hyperactive peripheral blood monocytes are a significant risk factor for the development of coronary heart disease.It is probably at least as important to reduce the reactivity of monocytes, and thus the production of pro-inflammatory products such as cytokines, oxidative metabolites and growth factors, as it is to reduce the cholesterol level. New studies also show that the anti-inflammatory effect of statins may be more important than their cholesterol reducing effect (Balk et al. "Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review" Ann Intern Med. 2003; 139:670-82. Review).The worldwide epidemic increase in obesity associated with energy-rich diets with sugar and saturated fats has led to a strong increase in so-called "non-alcoholic fatty liver disease" (NAFLD). NAFLD is considered to be the most serious form of chronic liver disease. Non-alcoholic steatohepatitis (NASH) is the most serious form of NAFLD, characterized by steatosis associated with inflammation, which can develop into liver fibrosis.It is today the second most common cause of liver transplantation in the United States of America and is expected to be the leading cause by 2020. No single treatment has been approved for treatment of NASH.Omega-3 fatty acids are known to reduce the risk of arrhythmia which can lead to sudden death. Omega-3 fatty acids are also known to reduce the risk of thrombosis which can lead to heart attack and stroke. They reduce the growth rate of atherosclerotic plaque, and thus have anti-inflammatory properties as lesion formation in the atherogenic process is mediated by pro-inflammatory reactions. Furthermore, omega-3 fatty acids improve endothelial function, reduce the level of triglycerides in the blood and lower the blood pressure slightly (for a brief overview, reference is made to PM Kris-Etherton, WS Harris, LJ Appell "Arterioscler Thromb Vase Biol." 2003; 23:151-2). In view of the properties of omega-3 fatty acids, it would be expected that a supplement of omega-3 fatty acids ought to be sufficient to prevent cardiovascular disease. However, clinical studies carried out in Norway have shown negative effects of omega-3 fatty acids (I Seljefot, 0 Johansen, H Arnesen, JB Eggesbo, AB Westvil, P Kierulf, "Thromb Haemost." 1999; 81:566-70; 0 Johansen, I Seljefot, AT Hostmark, H Arnesen "Arterioscler Thromb Vase Biol." 1999; 19; 1681-6). Patients with cardiovascular disease who were given a supplement of omega-3 fatty acids for six months experienced a doubling of both angina and occlusions compared with controls. An increase in cytokine production was also observed, which is indicative of an increase in pro-inflammatory peroxidation of polyunsaturated fatty acids in vivo (for an overview, reference is made to H. Arnesen, "Lipids" 2001; 36 Suppl: S103-6).The findings referred to above are in accordance with the inventor's own results with respect to diets including a supplement of omega-3 fatty acids. Thus, the antiinflammatory effect of supplementing the diet of healthy individuals with an omega-3 fatty acid concentrate was not significant compared with a corresponding amount of omega-3 fatty acids in the form of cod-liver oil (CLO).Although, many attempts have been made to find ways to prevent and treat the disorders and diseases discussed above, and a number of products are offered in this respect, there is still a need to provide improved and more effective products.WO 2006/118463 discloses a combination of seal oil and cold-pressed virgin olive oil showing potential to increase the beneficial HDL cholesterol, reducing the marker and risk factor for CHD, as well as reducing pro-inflammatory products.WO 2010/149815 discloses functional oil based on olive oil (87-96 %) and one or more ingredients selected from: avocado oil, argan oil, safflower oil, wheatgerm oil, krill oil, linseed oil, walnut oil, pumpkin seed oil, propolis oil, sesame oil and soya isoflavone; coenzyme Q-10; vitamin E; vitamin D; lycopene; vitamin K; vitamin A; EPA, DHA and mixtures thereof. Use of said functional oil as a medicinal product for the treatment and/or prophylaxis of inter alia coronary diseases, cardiovascular diseases (e.g. hypertension and thrombosis), inflammatory processes and atherosclerosis are described. Yang et al. (“Dietary marine-derived long-chain monounsaturated fatty acids and cardiovascular disease risk: a mini review”, Lipids in Health and Disease (2016) 15:201) reports that regular fish/fish oil consumption is widely recommended for protection of cardiovascular diseases (CVD). Fish and other marine life are rich sources of the cardioprotective long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic acid (C20:5 n-3, EPA) and docosahexaenoic acid (C22:6 n-3; DHA). The lipid content and fatty acid profile of fish, however, vary greatly among different fish species. In addition to n-3 PUFA, certain fish, such as saury, pollock and herring, also contain high levels of long-chain monounsaturated fatty acids (LCMUFA), with aliphatic tails longer than 18 C atoms (i.e. C20:1 and C22:1 isomers). A limited number of in vivo animal studies have provided valuable evidence supporting the potential for LCMUFA rich diet in the prevention of life-style related diseases, such as type 2 diabetes, metabolic syndrome and atherosclerosis. A few human studies have also suggested a possible link between LCMUFA-rich diet and CVD risk protection.In addition, B. Ruyter and A. Nilsson, researchers at Nofima have found that feeding salmon with herring oil rich in the 22:1(n-11) fatty acid, cetoleic acid, reduced fatty liver in salmons.Now, the inventor has surprisingly found that by combining cold-pressed virgin olive oil and herring oil, and optionally one or more omega-3 fatty acids selected form DHA (docosahexaenoic acid (22:6 n-3)), EPA (eicosapentaenoic acid (20:5 n-3)) and DPA (docosapentaenoic acid (22:5 n-3)), a product exhibiting enhanced effect with regard to prevention and/or treatment of at least one of atherosclerosis and NASH, is obtained.SUMMARY OF THE INVENTIONIt is a main object of the present invention to provide a food/dietary supplement to counteract the development of CHD, thrombosis and other inflammatory diseases such as psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia etc. and NAFLD.Another object of the present invention is to provide a combination or pharmaceutical composition useful in prevention or treatment of CHD, thrombosis and other inflammatory diseases such as psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia etc. and NAFLD. Still another object of the present invention is to provide a combination of oils useful as or in supplements and pharmaceuticals with improved functional properties and longer storage life.These and other objects are obtained by the combination as defined in the accompanying claims.DETAILED DESCRIPTION OF THE INVENTIONThe present invention provides a combination of oils comprising herring oil and cold-pressed virgin olive oil, wherein the combination comprises from 20% to 80% herring oil based on the total weight of the combination.In one embodiment of the invention, the ratio of herring oil to virgin olive oil in the combination is from 1:9 to 9:1, preferably 2:8 to 8: 2, more preferably 3:7 to 7:3, even more preferably 4:6 to 6:4, and most preferably 1:1.In another embodiment of the invention, the combination comprises more preferred from 30% to 60% herring oil and most preferred from 40% to 50% herring oil based on the total weight of the combination.In yet another embodiment of the invention, the combination comprises from 20% to 80% cold-pressed virgin olive oil, more preferred from 30% to 70% cold-pressed virgin olive oil and most preferred from 50% to 60% cold-pressed virgin olive oil based on the total weight of the combination.In a preferred embodiment of the invention, the combination further comprises one or more omega-3 fatty acids selected from EPA, DHA, and DPA to give a final total concentration of the omega-3 fatty acids in the combination of more than 1 gram per day.Thus, in a further embodiment of the invention, the combination comprises from 0% to 40% omega-3 fatty acids selected from EPA, DHA and DPA, more preferred from 10% to 40% and most preferred from 20% to 35% omega-3 fatty acids selected from EPA, DHA and DPA based on the total weight of the combination. The total content of the selected EPA, DHA and DPA is 70-80 g/100 ml oil where DHA is about three times higher than EPA, and DPA is about half the concentration of EPA.The herring oil and cold-pressed virgin olive oil are combined in ratios of 50% of each as the optimal combination. When omega-3 fatty acids are present, the combination may comprise 33% of herring oil and 33% of cold-pressed virgin olive oil in combination with 33% of omega-3 fatty acids enriched in DHA and DPA from fish oil.Furthermore, the present invention relates to the use of the said combination as a food supplement, dietary supplement, an edible oil, or a component of an oil-in-water or water-in-oil emulsion in foodstuffs.In another aspect the present invention provides the said combination for use in treatment or prophylaxis of diseases or disorders selected from the group consisting of atherosclerosis, coronary heart disease, thromboses, psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia, other pro-inflammatory diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver fibrosis.In a preferred embodiment of the invention, the diseases or disorders are selected from the group consisting of atherosclerosis, coronary heart disease, thromboses, psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia and other pro-inflammatory diseases.In another preferred embodiment of the invention, the diseases or disorders are selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and liver fibrosis.The combination according to the invention combines the effect of omega-3 fatty acids, monounsaturated fatty acids and a synergistic component which gives an antioxidation effect both in vivo and in vitro. This combination has advantageous properties in the form of better functional properties and longer storage life. The inventor has shown that a particularly advantageous effect is obtained using a product that comprises oil from herring and cold-pressed virgin olive oil, both of these components being manufactured in a known manner. The effect obtained is to be more pronounced than would be expected if each component were used alone. Thus, the invention relates to a combination of oils as a supplement to a regular diet, comprising a combination of herring oil and cold-pressed virgin olive oil with and without added additionally omega-3 fatty acids, DHA, EPA and DPA.What distinguishes herring oil from most other marine oils is that, in addition to comprising the omega-3 fatty acids EPA and DHA, it is rich in the long-chain monounsaturated fatty acids 20:1 and 22:1.The cold pressed olive oil used in the combination of the invention, is characterized in that it has a great potential to prevent oxidation of polyunsaturated fatty acids measured in Oxidograph at 70 °C when the olive oil is combined with marine oils rich in omega-3 fatty acids. The qualities of olive oil are mainly due to its high content of monounsaturated fatty acids, especially oleic acid (18:1 n-7, n-9), vitamins A,E, D and K, and polyphenols with antioxidant activity (hydroxytyosol, tyrosol) secoirdoides (oleuropein), lignans (acetoxipinoresinol, pinoresinol, flavones, pigments and betacarotene. That is, it is very rich in highly potent fat-soluble antioxidants. The olive oil in the combination of the invention is also distinguished by the high level of the antioxidant oleocanthal which gives the combination of the invention a very characteristic bitter taste and this component in olive oil has been shown to have a number of interesting effects in itself (Parkinson and Keast, Int. J. Mol. Sci.2014; 15, 12323 -12334, Review).The invention is explained in more detail in the examples below.EXAMPLESExample 1A mouse study was conducted at TNO, Leiden, The Netherlands on the effect of adding the combination of the invention based on the combination of refined herring oil and cold-pressed virgin olive oil to the diet and comparing the effects with corn oil.The ratio of herring oil to cold-pressed virgin olive oil in the combination of the invention used in the study was 50:50. A total amount of 1% of the oils was added to the diet. In the control, 1 % of corn oil was added to the diet.The study was done by comparing the effect of the nutrient oil on reducing the development of lesions (atherosclerosis) in apoE - / - mice (Apo3Leiden mice) fed with a fat diet with 0.25% cholesterol for 20 weeks as well as on the cellular and biochemical processes involved in the development of atherosclerosis with a corn oil as a control. At first, the mice were raised to the age of 12 weeks where the mice were put on a 3 week high cholesterol diet with 15% saturated fat and 1% (w / w) cholesterol. There were 20 mice in each group.The results of the nutrient effect on lesions (atherosclerosis) showed that the combination of the invention reduced the formation of lesions by 49% (p <0.001).Example 2TNO, Leiden, The Netherlands, has developed, along with human liver pathologists, two validated diet-induced NASH models that also develop liver fibrosis over time and a general measurement system for female mice (Liang et al., Lab Invest 2014, 94: 491-502; Liang et al. All PLoS ONE 20149 (12): e115922). The models have mapped the time in the development of the disease and mimic all the features of human pathology. NASH begins to develop after 12-16 months and liver fibrosis after 20-24 months.Since inflammation is an essential factor in the development of this disease, it was of great interest to test both scientifically and, not least, the health aspect of the NASH models of the combination of the present invention with a very potent antiinflammatory effect, to see whether the invention oil could hinder the development of NASH and liver fibrosis. As a control, corn oil was used. The same concentrations of the oils as indicated in Example 1 were used in this study.The mice used for the studies of atherosclerosis in Example 1 were also analysed for liver injury, NASH and fibrosis measurements by histopathology after 20 weeks of feeding.The results of the study showed:25% reduction in so-called macrovascular steatosis (p <0.003) 23.3% reduction in microvascular steatosis33.9% reduction in hypertrophyLiver lipids decreased by 72.9% (p = 0.026)Despite the fact that the NASH model was not optimal in this case (should be used higher amounts of fat that makes it more sensitive), the study showed that the combination of the invention has a very beneficial effect to reduce NASH. A reduction on NASH is very important in limiting the damaging effect of overweight that is constantly increasing throughout the world.The conclusion is that the combination of the invention has the potential to prevent atherosclerosis and to reduce the harmful effects of fatty liver caused by increased fat intake.
Claims
Patent claims1.A combination of oils, c h a r a c t e r i z e d i n t h a t it comprises herring oil and cold-pressed virgin olive oil, wherein the combination comprises from 20% to 80% herring oil based on the total weight of the combination.2.The combination according to claim 1, c h a r a c t e r i z e d i n t h a t it further comprises one or more omega-3 fatty acids selected from EPA, DHA, and DPA.3.The combination according to claim 1, c h a r a c t e r i z e d i n t h a t the ratio of herring oil to cold-pressed virgin olive oil is from 1:9 to 9:1, preferably 2:8 to 8: 2 , more preferably 3:7 to 7:3, even more preferably 4:6 to 6:4, and most preferably 1:1.4.The combination according to claim 1 or 2 , c h a r a c t e r i z e d i n t h a t it comprises:- from 20% to 80% herring oil, preferably from 30% to 60% herring oil and more preferably from 40% to 50% herring based on the total weight of the combination;- from 20% to 80% cold-pressed olive oil, preferably from 30% to 70% coldpressed olive oil and more preferably from 50% to 60% cold-pressed olive oil based on the total weight of the combination; and- from 0% to 40% omega-3 fatty acids selected from EPA, DHA and DPA, preferably from 10% to 40% and more preferably from 20% to 35% omega-3 fatty acids selected from EPA, DHA and DPA based on the total weight of the combination.5.The use of the combination according to any one of claims 1-4, as a food supplement, dietary supplement, an edible oil, or a component of an oil-in-water or water-in-oil emulsion in foodstuffs.6.The combination according to any one of claims 1-4, for use in treatment or prophylaxis of diseases or disorders selected from the group consisting of atherosclerosis, coronary heart disease, thromboses, psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia, other pro-inflammatory diseases, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and liver fibrosis.7.The combination according to claim 6, wherein the diseases or disorders are selected from the group consisting of atherosclerosis, coronary heart disease, thromboses, psoriasis, rheumatoid arthritis, osteoarthritis, fibromyalgia and other pro-inflammatory diseases.8.The combination according to claim 6, wherein the diseases or disorders are selected from the group consisting non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver fibrosis.Patentkrav1.Kombinasjon av oljer, k a r a k t e r i s e r t v e d a t den innbefatter sildeolje og kaldpresset jomfruelig olivenolje, der kombinasjonen innbefatter fra 20% til 80% sildeolje basert på totalvekten av kombinasjonen.2.Kombinasjon ifølge krav 1, k a r a k t e r i s e r t v e d a t den videre innbefatter én eller flere omega-3 fettsyrer valgt fra EPA, DHA og DPA.3.Kombinasjon ifølge krav 1, k a r a k t e r i s e r t v e d a t forholdet mellom sildeolje og kaldpresset jomfruelig olivenolje er fra 1:9 til 9:1, foretrukket 2:8 til 8: 2, mer foretrukket 3:7 to 7:3, enda mer foretrukket 4:6 to 6:4, og mest foretrukket 1:1.4.Kombinasjon ifølge krav 1 eller 2, k a r a k t e r i s e r t v e d a t den innbefatter:- fra 20% til 80% sildeolje, foretrukket fra 30% til 60% sildeolje og mer foretrukket fra 40% til 50% sildeolje basert på totalvekten av kombinasjonen;- fra 20% til 80% kaldpresset jomfruelig olivenolje, foretrukket fra 30% til 70% kaldpresset olivenolje og mer foretrukket fra 50% til 60% kaldpresset olivenolje basert på totalvekten av kombinasjonen; og- fra 0% til 40% omega-3 fettsyrer valgt fra EPA, DHA og DPA, foretrukket fra 10% til 40% og mer foretrukket fra 20% til 35% omega-3 fettsyrer valgt fra EPA, DHA og DPA basert på totalvekten av kombinasjonen.5.Anvendelse av kombinasjonen ifølge et hvilket som helst av kravene 1-4, som et næringstilskudd, kosttilskudd, en spiselig olje, eller en komponent til en olje-i-vanneller vann-i-olje-emulsjon i næringsmidler.6.Kombinasjon ifølge et hvilket som helst av kravene 1-4, for anvendelse ved behandling eller profylakse av sykdommer eller lidelser valgt fra gruppen bestående av aterosklerose, koronar hjertesykdom, tromboser, psoriasis, reumatoid artritt, osteoartritt, fibromyalgi, andre pro-inflammatorisk sykdommer, nonalkoholisk fettlever (NAFLD), nonalkoholisk steatohepatittt (NASH) og leverfibrose.7.Kombinasjon ifølge krav 6, der sykdommene eller lidelsene er valgt fra gruppen bestående av aterosklerose, koronar hjertesykdom, tromboser, psoriasis, reumatoid artritt, osteoartritt, fibromyalgi og andre pro-inflammatorisk sykdommer.8.Kombinasjon ifølge krav 6, der sykdommene eller lidelsene er valgt fra gruppen bestående av nonalkoholisk fettlever (NAFLD), nonalkoholisk steatohepatittt (NASH) og leverfibrose.

Priority

No priority

Patent classes

IPC classesA23D 9/00A61K 35/60A61K 36/63CPC classesA23D 9/00A61K 35/60A61K 36/63

Citations

NO 20041197 A (A)Clinical Nutrition, 1999, vol. 18, nr. 3, s. 167-174, Ramirez-Tortosa, M. C. et al. ()European Food Research Technology, 2003, 217 (4), s. 301-307, Medina, I. et al. ()Lipids, 1998, 33 (4), s. 427-436, Vognhild, E. et al. ()GB 207545 A (A)EP 2320949 B1 (B1)NO 324534 B1 (B1)NO 322342 B1 (B1)CA 1336867 C (C)

Applicants, owners and inventors

Owners
ARCTIC OMEGA 3 NORWAY AS
Postboks 551 9256 TROMSØ NO (TROMSØ Municipality, Troms county)Org. number: 924411678Inventors
Bjarne Østerud
Grønlandsveien 26 9013 TROMSØ NO (TROMSØ Municipality, Troms county)

Agent

ZACCO NORWAY AS
ZACCO NORWAY AS

Org. number: 982702887

Name and address are automatically synchronized with the Brønnøysund Register Centre.

Open in The Brønnøysund Register Centre
Postboks 488 0213 OSLO NO (OSLO Municipality, Oslo county)
Org. number: 982702887
Reference: P61701749NO00

Status history

Payment history

Oppositions and appeals

No oppositions or appeals

Administrative limitation

No administrative limitation

Liens and licences

No liens or licenses registered

Gazette entries

No Gazette entries foundOnly events from 2024.03.04 and onwards are shown.